Literature DB >> 11552911

Lansoprazole in children: pharmacokinetics and efficacy in reflux oesophagitis.

C Faure1, L Michaud, E K Shaghaghi, M Popon, M Laurence, J F Mougenot, R Hankard, J Navarro, E Jacoz-Aigrain.   

Abstract

BACKGROUND: Data on the proton pump inhibitor lansoprazole in paediatric patients are limited. AIM: To investigate the pharmacokinetics, optimal dosage and efficacy of lansoprazole in paediatric patients.
METHODS: A 24-h gastric pH recording and a pharmacokinetic study were performed after 7 days of lansoprazole, 17 mg/m2, in 23 patients with reflux oesophagitis (median age, 3.5 years). Response was defined as pH > 3 for > 65% of the recording. The dosage was doubled in non-responders. Patients with no response on day 14 were excluded. Responders underwent endoscopy after 4 weeks on the response-inducing dosage; abnormal findings led to a repeat endoscopy after four additional weeks.
RESULTS: Nine patients responded to 17 mg/m2 and six to 30.3 mg/m2. On day 7, time with pH > 3 was significantly correlated with the area under the plasma concentration-time curve (P=0.003). The area under the plasma concentration-time curve was significantly greater in the nine responders to 17 mg/m2 than in the 14 other patients. Pharmacokinetic parameters were similar in responders and non-responders to the higher dose. After 4 weeks, oesophagitis was healed in 80% of responders. Adverse events occurred in three patients and required treatment discontinuation in one.
CONCLUSIONS: Lansoprazole is effective and safe in children. The optimal starting dosage is 30 mg/m2 or 1.4 mg/kg.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11552911     DOI: 10.1046/j.1365-2036.2001.01076.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  15 in total

Review 1.  GERD in the pediatric patient: management considerations.

Authors:  David A Gremse
Journal:  MedGenMed       Date:  2004-05-05

2.  Population pharmacokinetics of intravenous pantoprazole in paediatric intensive care patients.

Authors:  Géraldine Pettersen; Mohamad-Samer Mouksassi; Yves Théorêt; Line Labbé; Christophe Faure; Bao Nguyen; Catherine Litalien
Journal:  Br J Clin Pharmacol       Date:  2008-10-23       Impact factor: 4.335

3.  Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study.

Authors:  Vasundhara Tolia; Nader N Youssef; Mark A Gilger; Barry Traxler; Marta Illueca
Journal:  BMC Pediatr       Date:  2010-06-11       Impact factor: 2.125

4.  Gastroesophageal reflux in children: pathogenesis, prevalence, diagnosis, and role of proton pump inhibitors in treatment.

Authors:  Benjamin D Gold; James W Freston
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

5.  Age-dependent pharmacokinetics of lansoprazole in neonates and infants.

Authors:  Weijiang Zhang; Michael Kukulka; Galen Witt; Debra Sutkowski-Markmann; Janine North; Stuart Atkinson
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

6.  Safety and pharmacodynamics of lansoprazole in patients with gastroesophageal reflux disease aged <1 year.

Authors:  Margaret Springer; Stuart Atkinson; Janine North; Marsha Raanan
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

Review 7.  Lansoprazole: in the management of gastroesophageal reflux disease in children.

Authors:  Lesley J Scott
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 8.  The use of proton pump inhibitors in children: a comprehensive review.

Authors:  Troy E Gibbons; Benjamin D Gold
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

9.  Taste comparisons for lansoprazole strawberry-flavoured delayed-release orally disintegrating tablet and ranitidine peppermint-flavoured syrup in children.

Authors:  Vasundhara Tolia; Cong Han; Janine D North; Fouad Amer
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

10.  Off-label use of medicines in children: can available evidence avoid useless paediatric trials? The case of proton pump inhibitors for the treatment of gastroesophageal reflux disease.

Authors:  Giovanni Tafuri; Francesco Trotta; Hubert G M Leufkens; Nello Martini; Luciano Sagliocca; Giuseppe Traversa
Journal:  Eur J Clin Pharmacol       Date:  2008-09-17       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.